Neuroendocrine tumours: open trials in Canada

16 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Arthur J.E. Child Comprehensive Cancer Centre (Site 0203), Calgary · Princess Margaret Cancer Centre (Site 0202), Toronto
Registry updated 2026-11-03
NCT05773274
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
London Regional Cancer Program, London · Ottawa Hospital and Cancer Center-General Campus, Ottawa · CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Québec · Doctor H. Bliss Murphy Cancer Centre, St. John's · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto · BCCA - Vancouver Cancer Centre, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-11-03
NCT07165132
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Trial Treatment · Phase 1 · RayzeBio, Inc.
Montreal · Toronto
Registry updated 2026-11-03
NCT06943755
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Trial Treatment · Phase 2/3 · Exelixis
Verspeeten Family Cancer Center - London Health Sciences Centre, London · The Ottawa Hospital Cancer Center, Ottawa · Sunnybrook Health Sciences Centre, Toronto
Registry updated 2026-10-30
NCT07544654
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Trial Treatment · Phase 3 · Boehringer Ingelheim
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Sunnybrook Health Sciences Centre, Toronto
Registry updated 2026-10-28
NCT05687123
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Trial Treatment · Phase 1 · National Cancer Institute (NCI)
University Health Network, Princess Margaret Hospital, Toronto
Registry updated 2026-10-20
NCT07621146
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Research · British Columbia Cancer Agency
BC Cancer - Vancouver, Vancouver
Registry updated 2026-10-06
NCT05196087
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Research · University Health Network, Toronto
Princess Margaret Cancer Centre, Toronto
Registry updated 2026-09-28
NCT07006727
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Trial Treatment · Phase 1 · Novartis Pharmaceuticals
Montreal
Registry updated 2026-09-22
NCT06784752
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Edmonton · London · Montreal · Toronto
Registry updated 2026-09-11
NCT06345079
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Trial Treatment · Phase 2 · Australasian Gastro-Intestinal Trials Group
Cross Cancer Institute, Edmonton · London Health Sciences Centre Research Institute (LHSCRI), London · Ottawa Hospital Research Institute, Ottawa · Allan Blair Cancer Centre, Regina · Saskatoon Cancer Centre, Saskatoon · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto · University Health Network - Princess Margaret Cancer Centre, Toronto · BC Cancer Agency, Vancouver Cancer Centre, Vancouver
Registry updated 2026-09-10
NCT02402244
Project: Every Child for Younger Patients With Cancer
Research · Children's Oncology Group
Alberta Children's Hospital, Calgary · University of Alberta Hospital, Edmonton · IWK Health Centre, Halifax · McMaster Children's Hospital at Hamilton Health Sciences, Hamilton · Kingston Health Sciences Centre, Kingston · Children's Hospital, London · The Montreal Children's Hospital of the MUHC, Montreal · Centre Hospitalier Universitaire Sainte-Justine, Montreal · Children'S Hospital Of Eastern Ontario, Ottawa · CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Québec · Jim Pattison Children's Hospital, Saskatoon · Saskatoon Cancer Centre, Saskatoon · Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke · Janeway Child Health Centre, St. John's · Hospital for Sick Children, Toronto · British Columbia Children's Hospital, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-08-25
NCT04888481
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Trial Treatment · Phase 2 · University of Alberta
University of Alberta, Edmonton
Registry updated 2026-05-11
NCT04706910
18F-DOPA II - PET Imaging Optimization
Trial Treatment · Phase 3 · University of Alberta
WC Mackenzie Health Science Centre / University of Alberta Hospital, Edmonton
Registry updated 2026-02-09
NCT06981455
Life Following Excision of Neuroendocrine Tumors
Research · Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre, Toronto
Registry updated 2025-05-20
NCT05673031
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Research · Alberta Health services
Foothills Medical Center 1403 29 St NW, Calgary
Registry updated 2023-01-05

All Neuroendocrine tumours trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error